Monoaminergic dysfunction in recreational users of dexamphetamine

European Neuropsychopharmacology

Volumn 23, Issue 11, 2013, Pages 1491-1502

  Schouw, M L J ^a,b   Caan, M W A ^a,b   Geurts, H M ^a   Schmand, B ^a   Booij, J ^a,b   Nederveen, A J ^a,b   Reneman, L ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cognition; Dextroamphetamine; Dopamine; Methylphenidate; PhMRI; SPECT

Indexed keywords

DEXAMPHETAMINE; DOPAMINE; DOPAMINE TRANSPORTER; N OMEGA FLUOROPROPYL 2BETA CARBOMETHOXY 3BETA (4 IODOPHENYL)NORTROPANE I 123; RADIOLIGAND; RECREATIONAL DRUG; UNCLASSIFIED DRUG;

ABSTINENCE; ADULT; ARTICLE; BEHAVIOR; BINDING SITE; BRAIN BLOOD FLOW; BRAIN REGION; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; DRUG ABUSE; DRUG WITHDRAWAL; HUMAN; IMAGING SYSTEM; LONG TERM EXPOSURE; MALE; MONOAMINERGIC SYSTEM; NEUROIMAGING; NEUROTOXICITY; NORADRENERGIC SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PHARMACOLOGICAL MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

COGNITION; DEXTROAMPHETAMINE; DOPAMINE; METHYLPHENIDATE; PHMRI; SPECT;

ADULT; BRAIN; CORPUS STRIATUM; DEXTROAMPHETAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DRUG USERS; EXECUTIVE FUNCTION; FUNCTIONAL NEUROIMAGING; HUMANS; IODINE RADIOISOTOPES; MALE; MEMORY; METHYLPHENIDATE; NEUROPSYCHOLOGICAL TESTS; TROPANES;

EID: 84886792736     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.01.005     Document Type: Article

References (61)

1. Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage 2007, 38:95-113.
2. Beck A.T. A systematic investigation of depression. Compr.Psychiatry 1961, 2:163-170.
3. Bellgrove M.A., Hawi Z., Kirley A., Gill M., Robertson I.H. Dissecting the attention deficit hyperactivity disorder (ADHD) phenotype: sustained attention, response variability and spatial attentional asymmetries in relation to dopamine transporter (DAT1) genotype. Neuropsychologia 2005, 43:1847-1857.
4. Berman S., O'Neill J., Fears S., Bartzokis G., London E.D. Abuse of amphetamines and structural abnormalities in the brain. Ann.N.Y.Acad.Sci. 2008, 1141:195-220.
5. 123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys. Synapse 1997, 27:183-190.
6. 123I]FP-CIT: a potent radioligand for imaging of dopamine transporters. Eur. J. Nucl. Med. 1998, 25:24-30.
7. 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. J. Nucl. Med. 2007, 48:359-366.
8. Booij J., Korn P., Linszen D.H., Van Royen E.A. Assessment of endogenous dopamine release by methylphenidate challenge using iodine-123 iodobenzamide single-photon emission tomography. Eur. J. Nucl. Med. 1997, 24:674-677.
9. Carver, C.S.,.W.T.L., 1994. Behavioral inhibition, behavioral activation, and affective responses to impending reward and punishment: The BIS/BAS scales. 67 ed., pp. 319-333.
10. Chalela J.A., Alsop D.C., Gonzalez-Atavales J.B., Maldjian J.A., Kasner S.E., Detre J.A. Magnetic resonance perfusion imaging in acute ischemic stroke using continuous arterial spin labeling. Stroke 2000, 31:680-687.
11. Chen Y.C., Galpern W.R., Brownell A.L., Matthews R.T., Bogdanov M., Isacson O., Keltner J.R., Beal M.F., Rosen B.R., Jenkins B.G. Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data. Magn. Reson. Med. 1997, 38:389-398.
12. Chen Y.I., Brownell A.L., Galpern W., Isacson O., Bogdanov M., Beal M.F., Livni E., Rosen B.R., Jenkins B.G. Detection of dopaminergic cell loss and neural transplantation using pharmacological MRI, PET and behavioral assessment. Neuroreport 1999, 10:2881-2886.
13. da Silva N., Szobot C.M., Anselmi C.E., Jackowski A.P., Chi S.M., Hoexter M.Q., Anselmi O.E., Pechansky F., Bressan R.A., Rohde L.A. Attention deficit/hyperactivity disorder: is there a correlation between dopamine transporter density and cerebral blood flow?. Clin. Nucl. Med. 2011, 36:656-660.
14. de Almeida J., Palacios J.M., Mengod G. Distribution of 5-HT and DA receptors in primate prefrontal cortex: implications for pathophysiology and treatment. Prog. Brain Res. 2008, 172:101-115.
15. (123)I]beta-CIT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram. Neuropsychopharmacology 2005, 30:996-1005.
16. de Win M.M., Jager G., Booij J., Reneman L., Schilt T., Lavini C., Olabarriaga S.D., Den Heeten G.J., van den Brink W. Sustained effects of ecstasy on the human brain: a prospective neuroimaging study in novel users. Brain 2008, 131:2936-2945.
17. Devous M.D., Trivedi M.H., Rush A.J. Regional cerebral blood flow response to oral amphetamine challenge in healthy volunteers. J. Nucl. Med. 2001, 42:535-542.
18. Gevers S., van Osch M.J., Bokkers R.P., Kies D.A., Teeuwisse W.M., Majoie C.B., Hendrikse J., Nederveen A.J. Intra- and multicenter reproducibility of pulsed, continuous and pseudo-continuous arterial spin labeling methods for measuring cerebral perfusion. J. Cereb. Blood Flow Metab. 2011, 31:1706-1715.
19. 11C]raclopride positron emission tomography study in cats. Biol. Psychiatry 2004, 55:1188-1194.
20. Golay X., Petersen E.T., Hui F. Pulsed star labeling of arterial regions (PULSAR): a robust regional perfusion technique for high field imaging. Magn. Reson. Med. 2005, 53:15-21.
21. Gulley J.M., Stanis J.J. Adaptations in medial prefrontal cortex function associated with amphetamine-induced behavioral sensitization. Neuroscience 2010, 166:615-624.
22. Han D.D., Gu H.H. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC. Pharmacol. 2006, 6:6.
23. Hannestad J., Gallezot J.D., Planeta-Wilson B., Lin S.F., Williams W.A., van Dyck C.H., Malison R.T., Carson R.E., Ding Y.S. Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo. Biol. Psychiatry 2010, 68:854-860.
24. Honey G.D., Suckling J., Zelaya F., Long C., Routledge C., Jackson S., Ng V., Fletcher P.C., Williams S.C., Brown J., Bullmore E.T. Dopaminergic drug effects on physiological connectivity in a human cortico-striato-thalamic system. Brain 2003, 126:1767-1781.
25. Jenkins B.G., Sanchez-Pernaute R., Brownell A.L., Chen Y.C., Isacson O. Mapping dopamine function in primates using pharmacologic magnetic resonance imaging. J. Neurosci. 2004, 24:9553-9560.
26. Jueptner M., Weiller C. Review: does measurement of regional cerebral blood flow reflect synaptic activity? Implications for PET and fMRI. Neuroimage 1995, 2:148-156.
27. Koda K., Ago Y., Cong Y., Kita Y., Takuma K., Matsuda T. Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice. J. Neurochem. 2010, 114:259-270.
28. Kuczenski R., Segal D.S. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J. Neurochem. 1997, 68:2032-2037.
29. Leroy C., Karila L., Martinot J.L., Lukasiewicz M., Duchesnay E., Comtat C., Dolle F., Benyamina A., Artiges E., Ribeiro M.J., Reynaud M., Trichard C. Striatal and extrastriatal dopamine transporter in cannabis and tobacco addiction: a high-resolution PET study. Addict. Biol. 2012, 17:981-990.
30. Leventhal A.M., Brightman M., Ameringer K.J., Greenberg J., Mickens L., Ray L.A., Sun P., Sussman S. Anhedonia associated with stimulant use and dependence in a population-based sample of American adults. Exp. Clin. Psychopharmacol. 2010, 18:562-569.
31. Martinez D., Narendran R., Foltin R.W., Slifstein M., Hwang D.R., Broft A., Huang Y., Cooper T.B., Fischman M.W., Kleber H.D., Laruelle M. Amphetamine-induced dopamine release: markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. Am. J. Psychiatry 2007, 164:622-629.
32. McCann U.D., Szabo Z., Vranesic M., Palermo M., Mathews W.B., Ravert H.T., Dannals R.F., Ricaurte G.A. Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance. Psychopharmacology (Berl) 2008, 200:439-450.
33. 11C]WIN-35,428. J. Neurosci. 1998, 18:8417-8422.
34. 18F]fluoro-L-DOPA-PET studies show partial reversibility of long-term effects of chronic amphetamine in monkeys. Synapse 1996, 22:63-69.
35. Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G. Dopamine receptors: from structure to function. Physiol. Rev. 1998, 78:189-225.
36. Nelson H.E. National Adult Reading Test. NFER-Nelson, 1982, Windsor, UK.
37. Nestler E.J. Molecular basis of long-term plasticity underlying addiction. Nat. Rev. Neurosci. 2001, 2:119-128.
38. Ogawa S., Lee T.M., Kay A.R., Tank D.W. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:9868-9872.
39. Ornstein T.J., Iddon J.L., Baldacchino A.M., Sahakian B.J., London M., Everitt B.J., Robbins T.W. Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers. Neuropsychopharmacology 2000, 23:113-126.
40. Patton J.H., Stanford M.S., Barratt E.S. Factor structure of the Barratt impulsiveness scale. J. Clin. Psychol. 1995, 51:768-774.
41. Rao S.M., Salmeron B.J., Durgerian S., Janowiak J.A., Fischer M., Risinger R.C., Conant L.L., Stein E.A. Effects of methylphenidate on functional MRI blood-oxygen-level-dependent contrast. Am. J. Psychiatry 2000, 157:1697-1699.
42. Rapeli P., Kivisaari R., Kahkonen S., Puuskari V., Autti T., Kalska H. Do individuals with former amphetamine dependence have cognitive deficits?. Nord. J. Psychiatry 2005, 59:293-297.
43. Reitan R. Trail Making Test: Manual for Administration, Scoring, and Interpretation 1956, Indiana University, Bloomington.
44. 123I]beta-CIT SPECT study-preliminary report. Psychopharmacology (Berl) 2002, 159:335-340.
45. Rey A. L' examen clinique en psychologie 1964, Presses Universitaires de France, Paris.
46. Ricaurte G.A., Mechan A.O., Yuan J., Hatzidimitriou G., Xie T., Mayne A.H., McCann U.D. Amphetamine treatment similar to that used in the treatment of adult attention-deficit/hyperactivity disorder damages dopaminergic nerve endings in the striatum of adult nonhuman primates. J. Pharmacol. Exp. Ther. 2005, 315:91-98.
47. Robbins T.W., Arnsten A.F. The neuropsychopharmacology of fronto-executive function: monoaminergic modulation. Annu. Rev. Neurosci. 2009, 32:267-287.
48. Rohde L.A., Roman T., Szobot C., Cunha R.D., Hutz M.H., Biederman J. Dopamine transporter gene, response to methylphenidate and cerebral blood flow in attention-deficit/hyperactivity disorder: a pilot study. Synapse 2003, 48:87-89.
49. Schmand B., Geerlings M.I., Jonker C., Lindeboom J. Reading ability as an estimator of premorbid intelligence: does it remain stable in emergent dementia?. J. Clin. Exp. Neuropsychol. 1998, 20:42-51.
50. Singer B.F., Tanabe L.M., Gorny G., Jake-Matthews C., Li Y., Kolb B., Vezina P. Amphetamine-induced changes in dendritic morphology in rat forebrain correspond to associative drug conditioning rather than nonassociative drug sensitization. Biol. Psychiatry 2009, 65:835-840.
51. Spencer T.J., Biederman J., Ciccone P.E., Madras B.K., Dougherty D.D., Bonab A.A., Livni E., Parasrampuria D.A., Fischman A.J. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am. J. Psychiatry 2006, 163:387-395.
52. 2O PET study in healthy volunteers. Hum. Brain Mapp. 2007, 28:625-635.
53. Vaidya C.J., Austin G., Kirkorian G., Ridlehuber H.W., Desmond J.E., Glover G.H., Gabrieli J.D. Selective effects of methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study. Proc. Natl. Acad. Sci. U.S.A 1998, 95:14494-14499.
54. Van den Heuvel D.M., Pasterkamp R.J. Getting connected in the dopamine system. Prog. Neurobiol. 2008, 85:75-93.
55. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Franceschi D., Sedler M.J., Gatley S.J., Hitzemann R., Ding Y.S., Wong C., Logan J. Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers. Am. J. Psychiatry 2001, 158:383-389.
56. Volkow N.D., Wang G.J., Fowler J.S., Gatley S.J., Logan J., Ding Y.S., Hitzemann R., Pappas N. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am. J. Psychiatry 1998, 155:1325-1331.
57. Volkow N.D., Wang G.J., Fowler J.S., Logan J., Angrist B., Hitzemann R., Lieberman J., Pappas N. Effects of methylphenidate on regional brain glucose metabolism in humans: relationship to dopamine D2 receptors. Am. J. Psychiatry 1997, 154:50-55.
58. Volkow N.D., Wang G.J., Ma Y., Fowler J.S., Wong C., Ding Y.S., Hitzemann R., Swanson J.M., Kalivas P. Activation of orbital and medial prefrontal cortex by methylphenidate in cocaine-addicted subjects but not in controls: relevance to addiction. J. Neurosci. 2005, 25:3932-3939.
59. Wang G.J., Volkow N.D., Fowler J.S., Ferrieri R., Schlyer D.J., Alexoff D., Pappas N., Lieberman J., King P., Warner D. Methylphenidate decreases regional cerebral blood flow in normal human subjects. Life Sci. 1994, 54:L143-L146.
60. Wang J., Alsop D.C., Li L., Listerud J., Gonzalez-At J.B., Schnall M.D., Detre J.A. Comparison of quantitative perfusion imaging using arterial spin labeling at 1.5 and 4.0T. Magn. Reson. Med. 2002, 48:242-254.
61. 2I. J. Nucl. Med. 2010, 51:1885-1891.